William K. Heiden Acquires 100,000 Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Director William K. Heiden bought 100,000 shares of Atara Biotherapeutics stock in a transaction dated Friday, November 10th. The shares were acquired at an average cost of $0.25 per share, for a total transaction of $25,000.00. Following the completion of the purchase, the director now directly owns 209,000 shares of the company’s stock, valued at approximately $52,250. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Atara Biotherapeutics Trading Up 9.3 %

NASDAQ ATRA opened at $0.38 on Thursday. Atara Biotherapeutics, Inc. has a 12 month low of $0.20 and a 12 month high of $5.64. The stock has a market cap of $38.75 million, a P/E ratio of -0.14 and a beta of 0.98. The stock’s fifty day moving average price is $1.36 and its 200-day moving average price is $1.73.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.03). Atara Biotherapeutics had a negative net margin of 6,390.31% and a negative return on equity of 783.31%. The business had revenue of $2.14 million for the quarter, compared to analysts’ expectations of $2.20 million. As a group, analysts forecast that Atara Biotherapeutics, Inc. will post -2.62 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ATRA. State Street Corp lifted its holdings in Atara Biotherapeutics by 45.1% in the first quarter. State Street Corp now owns 6,273,617 shares of the biotechnology company’s stock valued at $58,282,000 after acquiring an additional 1,949,418 shares during the period. Wasatch Advisors Inc. raised its stake in shares of Atara Biotherapeutics by 88.8% in the first quarter. Wasatch Advisors Inc. now owns 3,823,588 shares of the biotechnology company’s stock worth $35,521,000 after buying an additional 1,798,072 shares during the period. Renaissance Technologies LLC raised its stake in shares of Atara Biotherapeutics by 771.3% in the first quarter. Renaissance Technologies LLC now owns 1,437,700 shares of the biotechnology company’s stock worth $4,169,000 after buying an additional 1,272,700 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Atara Biotherapeutics by 41.9% in the first quarter. Goldman Sachs Group Inc. now owns 3,638,106 shares of the biotechnology company’s stock worth $33,798,000 after buying an additional 1,073,579 shares during the period. Finally, Baupost Group LLC MA raised its stake in shares of Atara Biotherapeutics by 12.3% in the first quarter. Baupost Group LLC MA now owns 9,123,616 shares of the biotechnology company’s stock worth $26,458,000 after buying an additional 1,000,000 shares during the period. Institutional investors own 88.79% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Evercore ISI cut Atara Biotherapeutics from an “outperform” rating to an “in-line” rating in a research note on Thursday, November 9th. StockNews.com raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, November 2nd. HC Wainwright cut Atara Biotherapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, November 9th. Finally, Mizuho cut Atara Biotherapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, November 9th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $28.00.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.